KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Payables (2016 - 2025)

Historic Payables for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $5.0 billion.

  • Pfizer's Payables fell 545.73% to $5.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 billion, marking a year-over-year decrease of 545.73%. This contributed to the annual value of $8.1 billion for FY2024, which is 1114.29% down from last year.
  • As of Q3 2025, Pfizer's Payables stood at $5.0 billion, which was down 545.73% from $7.6 billion recorded in Q2 2025.
  • Pfizer's Payables' 5-year high stood at $9.1 billion during Q4 2022, with a 5-year trough of $4.1 billion in Q2 2021.
  • In the last 5 years, Pfizer's Payables had a median value of $6.9 billion in 2021 and averaged $6.8 billion.
  • As far as peak fluctuations go, Pfizer's Payables surged by 3548.23% in 2022, and later plummeted by 3728.85% in 2023.
  • Quarter analysis of 5 years shows Pfizer's Payables stood at $7.8 billion in 2021, then rose by 16.42% to $9.1 billion in 2022, then decreased by 0.33% to $9.1 billion in 2023, then decreased by 11.14% to $8.1 billion in 2024, then plummeted by 37.74% to $5.0 billion in 2025.
  • Its last three reported values are $5.0 billion in Q3 2025, $7.6 billion for Q2 2025, and $5.2 billion during Q1 2025.